SARS‐COV‐2–associated coagulopathy and thromboembolism prophylaxis in children: A single‐center observational study

Multiple investigators have described an increased incidence of thromboembolic events in SARS‐CoV‐2–infected individuals. Data concerning hemostatic complications in children hospitalized for COVID‐19/multisystem inflammatory syndrome in children (MIS‐C) are scant.

[1]  Andrew E. Williams,et al.  Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study , 2020, medRxiv.

[2]  P. Monagle,et al.  Consensus‐based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID‐19–related illness , 2020, Journal of Thrombosis and Haemostasis.

[3]  J. Lipton,et al.  Are children with SARS‐CoV‐2 infection at high risk for thrombosis? Viscoelastic testing and coagulation profiles in a case series of pediatric patients , 2020, Pediatric blood & cancer.

[4]  K. Kain,et al.  COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department , 2020, Journal of Allergy and Clinical Immunology.

[5]  S. Nopp,et al.  Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis , 2020, Research and Practice in Thrombosis and Haemostasis.

[6]  E. Aronica,et al.  Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study , 2020, The Lancet Microbe.

[7]  C. Bradbury,et al.  Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study , 2020, Critical Care.

[8]  Marvin G. Chang,et al.  Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations , 2020, Critical Care.

[9]  S. Aronoff,et al.  The Natural History of Severe Acute Respiratory Syndrome Coronavirus 2–Related Multisystem Inflammatory Syndrome in Children: A Systematic Review , 2020, Journal of the Pediatric Infectious Diseases Society.

[10]  F. Ozturk,et al.  Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis , 2020, The American Journal of Emergency Medicine.

[11]  F. Piel,et al.  Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients , 2020, Haematologica.

[12]  Shruti Chaturvedi,et al.  Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition , 2020, Blood.

[13]  S. Gordon,et al.  Monocyte activation in systemic Covid-19 infection: Assay and rationale , 2020, EBioMedicine.

[14]  K. Wilson,et al.  COVID-19 and multisystem inflammatory syndrome in children and adolescents , 2020, The Lancet Infectious Diseases.

[15]  J. Merrill,et al.  Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications , 2020, Nature Reviews Rheumatology.

[16]  M. Rudelius,et al.  Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy , 2020, Circulation.

[17]  P. Prandoni,et al.  The hazard of (sub)therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience , 2020, Journal of Thrombosis and Haemostasis.

[18]  C. Righy,et al.  Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 , 2020, Blood.

[19]  L. Argaud,et al.  Hypofibrinolytic state and high thrombin generation may play a major role in SARS‐COV2 associated thrombosis , 2020, Journal of Thrombosis and Haemostasis.

[20]  S. Kahn,et al.  Anticoagulation practice patterns in COVID‐19: A global survey , 2020, Research and Practice in Thrombosis and Haemostasis.

[21]  Karlheinz Peter,et al.  The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications , 2020, Circulation research.

[22]  L. Mbuagbaw,et al.  Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. , 2020, Blood advances.

[23]  Robert A. Campbell,et al.  Platelet gene expression and function in patients with COVID-19 , 2020, Blood.

[24]  É. Azoulay,et al.  The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection , 2020, Critical Care.

[25]  D. Leaf,et al.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection , 2020, Blood.

[26]  P. Carmeliet,et al.  COVID-19: the vasculature unleashed , 2020, Nature Reviews Immunology.

[27]  R. DeBiasi,et al.  Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region , 2020, The Journal of Pediatrics.

[28]  M. Cabana,et al.  Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City , 2020, The Journal of Pediatrics.

[29]  P. Emery,et al.  Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.

[30]  E. Amankwah,et al.  In Children with Provoked Venous Thromboembolism, Increasing Plasma Coagulability during the First 3 Months Postdiagnosis is Prognostic of Recurrence , 2020, Thrombosis and Haemostasis.

[31]  G. Mahé,et al.  Emergence of institutional antithrombotic protocols for coronavirus 2019 , 2020, Research and Practice in Thrombosis and Haemostasis.

[32]  L. Beenen,et al.  Incidence of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[33]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[34]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[35]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[36]  W. Ageno,et al.  COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). , 2020, Blood transfusion = Trasfusione del sangue.

[37]  Troy Richardson,et al.  Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014. , 2018, Blood advances.

[38]  B. Gaines,et al.  Venous thromboembolism in pediatric trauma patients: Ten‐year experience and long‐term follow‐up in a tertiary care center , 2017, Pediatric blood & cancer.

[39]  R. Ichord,et al.  Thrombotic events in critically ill children with myocarditis , 2013, Cardiology in the Young.

[40]  P. Monagle,et al.  The Coagulation System in Children: Developmental and Pathophysiological Considerations , 2011, Seminars in thrombosis and hemostasis.

[41]  L. Brandão,et al.  Clinical probability score and D‐dimer estimation lack utility in the diagnosis of childhood pulmonary embolism , 2009, Journal of thrombosis and haemostasis : JTH.

[42]  C. Feudtner,et al.  Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States From 2001 to 2007 , 2009, Pediatrics.

[43]  G. Lippi,et al.  Help me, Doctor! My D-dimer is raised , 2008, Annals of medicine.

[44]  E. Young.  The anti-inflammatory effects of heparin and related compounds. , 2008, Thrombosis research.